IL28B 多态性对既往无应答或复发的 HIV-丙型肝炎病毒合并感染患者对聚乙二醇干扰素和利巴韦林反应的影响。
Impact of IL28B polymorphisms on response to peginterferon and ribavirin in HIV–hepatitis C virus-coinfected patients with prior nonresponse or relapse.
机构信息
Hospital Carlos III, Madrid, Spain.
出版信息
AIDS. 2011 May 15;25(8):1131-3. doi: 10.1097/QAD.0b013e3283471d83.
IL28B polymorphisms predict treatment response in chronic hepatitis C. However, no information exists in prior treatment failures. A total of 62 HIV/hepatitis C virus (HCV) patients who completed retreatment with peginterferon-α/ribavirin were examined, of whom 25 (40%) had been cured. Predictors of response [odds ratio, OR (95% confidence interval, CI)] were HCV genotypes 2/3 [16.1 (2.7-90.9)], prior relapse [9.6 (1.5-62.4)] and ribavirin plasma trough concentrations at week 4 [4.9 (1.3-18.4)]. IL28B-CC only predicted response in prior nonresponders carrying HCV genotypes 1/4 [25.1 (1.9-337)].
IL28B 多态性可预测慢性丙型肝炎的治疗反应。然而，在先前的治疗失败中没有相关信息。共检查了 62 例完成聚乙二醇干扰素-α/利巴韦林重新治疗的 HIV/丙型肝炎病毒 (HCV) 患者，其中 25 例（40%）治愈。反应的预测因子[比值比，OR（95%置信区间，CI）]包括 HCV 基因型 2/3 [16.1（2.7-90.9）]、先前复发[9.6（1.5-62.4）]和第 4 周利巴韦林血药浓度谷值[4.9（1.3-18.4）]。IL28B-CC 仅在携带 HCV 基因型 1/4 的先前无应答者中预测反应[25.1（1.9-337）]。
Zotero 插件